S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NYSE:EBS

Emergent BioSolutions Stock Forecast, Price & News

$106.29
+0.30 (+0.28 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$104.51
Now: $106.29
$107.93
50-Day Range
$81.14
MA: $90.98
$107.65
52-Week Range
$46.37
Now: $106.29
$137.61
Volume518,858 shs
Average Volume493,200 shs
Market Capitalization$5.63 billion
P/E Ratio34.18
Dividend YieldN/A
Beta1.26
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Emergent BioSolutions logo

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

359th out of 1,556 stocks

Pharmaceutical Preparations Industry

186th out of 638 stocks

Analyst Opinion: 1.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
CUSIP29089Q10
Phone240-631-3200
Employees1,834

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.11 billion
Cash Flow$5.09 per share
Book Value$21.08 per share

Profitability

Net Income$54.50 million

Miscellaneous

Market Cap$5.63 billion
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$106.29
+0.30 (+0.28 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Emergent BioSolutions (NYSE:EBS) Frequently Asked Questions

How has Emergent BioSolutions' stock been impacted by COVID-19 (Coronavirus)?

Emergent BioSolutions' stock was trading at $53.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EBS stock has increased by 100.4% and is now trading at $106.29.
View which stocks have been most impacted by COVID-19
.

Is Emergent BioSolutions a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Emergent BioSolutions stock.
View analyst ratings for Emergent BioSolutions
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Emergent BioSolutions?

Wall Street analysts have given Emergent BioSolutions a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Emergent BioSolutions wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Emergent BioSolutions' next earnings date?

Emergent BioSolutions is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Emergent BioSolutions
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) released its earnings results on Wednesday, November, 11th. The biopharmaceutical company reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.07. The biopharmaceutical company had revenue of $385.20 million for the quarter, compared to the consensus estimate of $438.51 million. Emergent BioSolutions had a net margin of 12.50% and a return on equity of 26.68%. The firm's revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.24 earnings per share.
View Emergent BioSolutions' earnings history
.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions updated its FY 2020 After-Hours earnings guidance on Thursday, November, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.52-1.58 billion, compared to the consensus revenue estimate of $1.53 billion.

What price target have analysts set for EBS?

7 equities research analysts have issued 12-month price targets for Emergent BioSolutions' stock. Their forecasts range from $67.00 to $112.00. On average, they expect Emergent BioSolutions' stock price to reach $96.00 in the next twelve months. This suggests that the stock has a possible downside of 9.7%.
View analysts' price targets for Emergent BioSolutions
or view Wall Street analyst' top-rated stocks.

Who are some of Emergent BioSolutions' key competitors?

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), salesforce.com (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Square (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

Who are Emergent BioSolutions' key executives?

Emergent BioSolutions' management team includes the following people:
  • Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 62, Pay $1.14M)
  • Mr. Robert G. Kramer, CEO, Pres & Exec. Director (Age 63, Pay $1.24M)
  • Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 56, Pay $821.36k)
  • Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 47, Pay $806.84k)
  • Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 49, Pay $789.23k)
  • Mr. Sean M. Kirk, Exec. VP of Manufacturing & Technical Operations
  • Ms. Sharon M. Solomon, Sr. VP & Chief Information Officer
  • Mr. Robert G. Burrows, VP of Investor Relations
  • Ms. Laura K. Kennedy, Sr. VP and Chief Ethics & Compliance Officer
  • Ms. Lynn Kieffer, VP of Corp. Communications

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.29%), Central Bank & Trust Co. (0.09%), Investment House LLC (0.09%), First Hawaiian Bank (0.02%), Crossmark Global Holdings Inc. (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own Emergent BioSolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends for Emergent BioSolutions
.

Which institutional investors are selling Emergent BioSolutions stock?

EBS stock was sold by a variety of institutional investors in the last quarter, including Coastal Investment Advisors Inc., First Hawaiian Bank, State of Alaska Department of Revenue, and Central Bank & Trust Co.. Company insiders that have sold Emergent BioSolutions company stock in the last year include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Ronald Richard, and Zsolt Harsanyi.
View insider buying and selling activity for Emergent BioSolutions
or view top insider-selling stocks.

Which institutional investors are buying Emergent BioSolutions stock?

EBS stock was purchased by a variety of institutional investors in the last quarter, including Scout Investments Inc., Crossmark Global Holdings Inc., New England Research & Management Inc., Investment House LLC, and Patriot Financial Group Insurance Agency LLC.
View insider buying and selling activity for Emergent BioSolutions
or or view top insider-buying stocks.

How do I buy shares of Emergent BioSolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $106.29.

How big of a company is Emergent BioSolutions?

Emergent BioSolutions has a market capitalization of $5.63 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $54.50 million in net income (profit) each year or $2.91 on an earnings per share basis. Emergent BioSolutions employs 1,834 workers across the globe.

What is Emergent BioSolutions' official website?

The official website for Emergent BioSolutions is www.emergentbiosolutions.com.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.